IN2014MN02269A - - Google Patents

Info

Publication number
IN2014MN02269A
IN2014MN02269A IN2269MUN2014A IN2014MN02269A IN 2014MN02269 A IN2014MN02269 A IN 2014MN02269A IN 2269MUN2014 A IN2269MUN2014 A IN 2269MUN2014A IN 2014MN02269 A IN2014MN02269 A IN 2014MN02269A
Authority
IN
India
Prior art keywords
relates
extract
composition
plant
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Arvind Saklani
Nilesh Malpure
Parikshit Gaikwad
Satish Namdeo Sawant
Tukaram Kisanrao Mane
Somesh Sharma
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2014MN02269A publication Critical patent/IN2014MN02269A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IN2269MUN2014 2012-04-23 2013-04-22 IN2014MN02269A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636792P 2012-04-23 2012-04-23
PCT/IB2013/053155 WO2013160811A1 (en) 2012-04-23 2013-04-22 Composition for treating metabolic disorders

Publications (1)

Publication Number Publication Date
IN2014MN02269A true IN2014MN02269A (ko) 2015-07-24

Family

ID=49482298

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2269MUN2014 IN2014MN02269A (ko) 2012-04-23 2013-04-22

Country Status (16)

Country Link
US (1) US20150290265A1 (ko)
EP (1) EP2841080A4 (ko)
JP (1) JP2015514797A (ko)
KR (1) KR20150003862A (ko)
CN (1) CN104244962A (ko)
AU (1) AU2013254329A1 (ko)
BR (1) BR112014026326A2 (ko)
CA (1) CA2870907A1 (ko)
IL (1) IL235317A0 (ko)
IN (1) IN2014MN02269A (ko)
MX (1) MX2014012742A (ko)
NZ (1) NZ701133A (ko)
RU (1) RU2014145931A (ko)
SA (1) SA113340494B1 (ko)
TW (1) TW201343174A (ko)
WO (1) WO2013160811A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233188A4 (en) * 2014-12-19 2018-11-07 Halo Life Science, LLC Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
EP3566055A4 (en) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN111757743A (zh) 2018-01-10 2020-10-09 布莱特西德公司 用于调节代谢的方法
KR20220100896A (ko) 2019-11-11 2022-07-18 브라이트씨드, 인크. 추출물, 소모가능 생성물 및 추출물에서 생물활성 대사산물을 농후화하는 방법
KR102408566B1 (ko) * 2020-04-09 2022-06-16 대한민국 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005053864A (ja) * 2003-08-06 2005-03-03 Ryukyu Bio Resource Kaihatsu:Kk 糖尿病疾患予防・治療剤
JP2006188486A (ja) * 2004-12-07 2006-07-20 Toyo Shinyaku:Kk 体脂肪蓄積抑制または低減剤
MX2007010322A (es) * 2005-02-23 2009-03-02 Avestha Gengraine Tech Pvt Ltd Extractos de planta y metodos y usos de los mismos.

Also Published As

Publication number Publication date
US20150290265A1 (en) 2015-10-15
NZ701133A (en) 2016-08-26
RU2014145931A (ru) 2016-06-20
WO2013160811A1 (en) 2013-10-31
EP2841080A4 (en) 2015-11-25
BR112014026326A2 (pt) 2017-06-27
KR20150003862A (ko) 2015-01-09
TW201343174A (zh) 2013-11-01
SA113340494B1 (ar) 2015-12-24
EP2841080A1 (en) 2015-03-04
MX2014012742A (es) 2015-04-08
AU2013254329A1 (en) 2014-11-13
CA2870907A1 (en) 2013-10-31
JP2015514797A (ja) 2015-05-21
IL235317A0 (en) 2014-12-31
CN104244962A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
IN2014MN02269A (ko)
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2014015004A (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2013114394A8 (en) A polyherbal composition for skin care
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
EP2575842A4 (en) COMPOSITION COMPRISING THE EXTRACT OF PHYSALIS ALKEKENGI VAR. FRANCHETI HORT AS AN ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES
WO2013175504A3 (en) Herbal composition for vaginal treatment
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
GB2498677A (en) Extracts of cynanchum SP.and active ingredients contained therein in use of arthritis treatment
IN2014MN01933A (ko)
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
WO2013038200A3 (en) Neurodevelopmental disorders
WO2012108747A3 (ko) 토목향 추출물을 포함하는 뇌암 치료용 조성물 및 화장료 조성물
IN2013MU03428A (ko)
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
UA48784U (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ПОЛОВЫХ РАССТРОЙСТВ|разлада| У ЖЕНЩИН
MX357329B (es) Extracto crudo de un hibrido de sechium edule, metodo para su extraccion y su uso para formulaciones con efecto antineoplasico.